next generation sequencing ngs library prep kit Search Results


next-generation rna sequencing-based mp/bp ngs kit  (Agendia BV)
90
Agendia BV next-generation rna sequencing-based mp/bp ngs kit
Patient sample inclusion diagram. Patient samples need to successfully pass different stages and quality controls before they can be included in the final analysis. Abbreviations: <t>NGS,</t> <t>next-generation</t> <t>sequencing;</t> QC, quality control; UHL, University Hospitals Leuven; CIP, Curie Institut Paris.
Next Generation Rna Sequencing Based Mp/Bp Ngs Kit, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next+generation+sequencing+ngs+library+prep+kit/next+generation+rna+sequencing+based+mp+bp+ngs+kit/pmc06742807-175-11-35
Average 90 stars, based on 1 article reviews
next-generation rna sequencing-based mp/bp ngs kit - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Patient sample inclusion diagram. Patient samples need to successfully pass different stages and quality controls before they can be included in the final analysis. Abbreviations: NGS, next-generation sequencing; QC, quality control; UHL, University Hospitals Leuven; CIP, Curie Institut Paris.

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: Patient sample inclusion diagram. Patient samples need to successfully pass different stages and quality controls before they can be included in the final analysis. Abbreviations: NGS, next-generation sequencing; QC, quality control; UHL, University Hospitals Leuven; CIP, Curie Institut Paris.

Article Snippet: In this beta testing study, we validated the Next-Generation RNA sequencing-based MP/BP NGS kit in UHL and CIP and we demonstrated reproducibility of the MP and BP NGS test between two independent decentralized laboratories and Agendia central laboratories.

Techniques: Next-Generation Sequencing

MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: MammaPrint (MP) microarray indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS indices at the beta sites. The comparison shows equivalence between the two technologies (Pearson's r = 0.96). The x-axis reports the MP microarray index, the y-axis reports the MP NGS index. Each dot represents a single breast cancer sample for which total RNA underwent microarray and NGS laboratory processing and analysis. The blue dots represent the discordant cases with indices close to the classification threshold.

Article Snippet: In this beta testing study, we validated the Next-Generation RNA sequencing-based MP/BP NGS kit in UHL and CIP and we demonstrated reproducibility of the MP and BP NGS test between two independent decentralized laboratories and Agendia central laboratories.

Techniques: Microarray

Comparison of molecular subtyping using MP and BP tests (Luminal A for Low Risk MP and Luminal B for High Risk) between NGS Beta Site and IHC according to Prat et al. (n = 124) ( A ), between NGS Beta Site and IHC according to Maisonneuve et al. (n = 124) ( B ), between NGS Beta Site and microarray Agendia (n = 124) ( C ), and between NGS Beta Site and NGS Agendia (n = 114 <xref ref-type= ∗ ) ( D ). These results show a concordance of 71.8% (89/124) ( A ), 76.6% (95/124) ( B ), 89.5% (111/124) ( C ) and 93.9% (107/114) ( D )." width="100%" height="100%">

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: Comparison of molecular subtyping using MP and BP tests (Luminal A for Low Risk MP and Luminal B for High Risk) between NGS Beta Site and IHC according to Prat et al. (n = 124) ( A ), between NGS Beta Site and IHC according to Maisonneuve et al. (n = 124) ( B ), between NGS Beta Site and microarray Agendia (n = 124) ( C ), and between NGS Beta Site and NGS Agendia (n = 114 ∗ ) ( D ). These results show a concordance of 71.8% (89/124) ( A ), 76.6% (95/124) ( B ), 89.5% (111/124) ( C ) and 93.9% (107/114) ( D ).

Article Snippet: In this beta testing study, we validated the Next-Generation RNA sequencing-based MP/BP NGS kit in UHL and CIP and we demonstrated reproducibility of the MP and BP NGS test between two independent decentralized laboratories and Agendia central laboratories.

Techniques: Microarray

MammaPrint (MP) NGS indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS at the beta sites. The comparison shows equivalence between MP NGS performed at Agendia (x-axis) and MP NGS at the beta sites (y-axis) (Pearson's r = 0.96) (n = 114). Each dot represents a single breast cancer sample for which total RNA underwent NGS or microarray laboratory processing and analysis. Out of the 124 samples processed on NGS, 10 samples lacked NGS results at Agendia. The blue dots represent the discordant cases with indices close to the classification threshold.

Journal: Translational Oncology

Article Title: Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

doi: 10.1016/j.tranon.2019.08.008

Figure Lengend Snippet: MammaPrint (MP) NGS indices assessed at Agendia Amsterdam central laboratory in comparison to MP NGS at the beta sites. The comparison shows equivalence between MP NGS performed at Agendia (x-axis) and MP NGS at the beta sites (y-axis) (Pearson's r = 0.96) (n = 114). Each dot represents a single breast cancer sample for which total RNA underwent NGS or microarray laboratory processing and analysis. Out of the 124 samples processed on NGS, 10 samples lacked NGS results at Agendia. The blue dots represent the discordant cases with indices close to the classification threshold.

Article Snippet: In this beta testing study, we validated the Next-Generation RNA sequencing-based MP/BP NGS kit in UHL and CIP and we demonstrated reproducibility of the MP and BP NGS test between two independent decentralized laboratories and Agendia central laboratories.

Techniques: Microarray